| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Division of Endocrinology, Department of Medicine, Johns Hopkins University School of Medicine, 1830 East Monument Street #333, Baltimore, Maryland 21287, USA 1 Division of Molecular Pharmaceutics, School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, USA
(Correspondence should be addressed to R Salvatori; Email: salvator{at}jhmi.edu)
* (A Sagazio is on leave from Department of Endocrinology and Metabolism, University G D'Annunzio, Chieti 66100, Italy) 
(Present address of Z Wang is at Department of Surgery, The Brooklyn Hospital Center, 121 Dekalb Avenue, Brooklyn, New York 11201, USA)
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Viral vectors provide more long-term effect than traditional drug therapy and represent an alternative efficient mechanism of delivery of proteins. Gene therapy approach to GHD animals has been studied using recombinant adenovirus vectors encoding murine or rat GH and single-stranded adeno-associated viral vectors (ssAAV; Hahn et al. 1996, Marmary et al. 1999, Rivera et al. 1999). The recombinant adenovirus used in the past often elicited a potent immune response, sometimes requiring administration of anti-inflammatory drugs to virus-treated animals (Adesanya et al. 1996), although with more modern vectors this problem is reduced (Alba et al. 2005b). In addition, the conventional AAV vectors tend to have delayed and less effective gene transfer and expression (Wang et al. 2003) because AAV DNA is packaged and delivered as a single-stranded genome, which is transcriptionally inactive until converted into double-stranded (ds) template. Recent research has focused on preparation of AAV vectors that can package a self-complementary dsDNA obtaining rapid, strong, and stable expression in animals (dsAAV; Berns & Hauswirth 1979, Berns & Giraurd 1995, Samulski et al. 1999). This overcomes the rate-limiting step of conversion of single into dsDNA. Non-pathogenicity, non-toxicity and lack of immune response, robust infectivity, and long-term gene transfer identify the new AAV vectors approach. AAV vectors are derived from the replication-defective parvovirus (Berns & Hauswirth 1979, Berns & Giraurd 1995, Samulski et al. 1999). The vectors carrying a foreign gene can infect both dividing and non-dividing cells in vitro and in vivo, obtaining a long-term transgenic expression minimizing the toxicity and cellular immune response (Ferrari et al. 1996, Afione et al. 1999, Bangari & Mittal 2006), resulting in robust and long-term delivery to many tissues, including muscle (Wang et al. 2005), liver (Song et al. 2001), and pancreas (McClane et al. 1997, Ayuso et al. 2004). These dsAAV vectors have successfully delivered gene therapy in animal models of diabetes (McClane et al. 1997, Ayuso et al. 2004, Rehman et al. 2005, Wang et al. 2006), muscular dystrophy (Zhu et al. 2005), hemophilia (Arruda et al. 2005), loss of corneal endothelium (Lai et al. 2005), and cerebral ischemia (Tsai et al. 2002), with possible important future applications in humans.
We have investigated whether such a new delivery system could be a tool to administer GH to GHD animals. We show that normalization of longitudinal growth can be achieved in GHD mice using a single injection of a dsAAV expressing mouse GH cDNA.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The AAV8-CMV-green fluorescent protein (GFP) vector (dsAAV8-CMV-GFP) was described earlier (Xiao et al. 1998, Gao et al. 2002). Full-length mouse cDNA was amplified by PCR from pituitary cDNA of a C57BL6 mouse using primers 5'-TTGGGGTCGAGGAAAACAGGTA-3' and 5'-GATGCATCTTAATTTTATTAGAGC-3', and inserted in pCR2.1 TA plasmid (Invitrogen). The dsAAV8-CMV-GH plasmid was generated by replacing the GFP gene of the dsAAV8-CMV-GFP (Wang et al. 2005) using BamHI/NotI restriction sites. The recombinant viral stocks were produced by the adenovirus-free, triple plasmid cotransfection method (Xiao et al. 1998). The AAV particles were subsequently purified by two rounds of CsCl gradient ultracentrifugation. The titer of viral genome particle number was determined by quantitative DNA dot bolt method (Snyder et al. 1996).
Animals and vector administration
We used homozygous GHRHKO male mice and heterozygous male carriers as normal controls to guarantee similar genetic background (mixed C57BL6/129SV; Alba & Salvatori 2004). Following guidance from previous studies (McClane et al. 1997, Song et al. 2001, Tsai et al. 2002, Ayuso et al. 2004, Arruda et al. 2005, Lai et al. 2005, Rehman et al. 2005, Zhu et al. 2005, Wang et al. 2006), dsAAV8-CMV-GH viruses were injected intraperitoneally at the 10th day of age. Treatment groups are described in Table 1. Low dose (LD) groups (12 GHRHKO pups per group) received 1x1011 particles of dsAAV8-CMV-GH viral particles; High dose (HD) group (6 GHRHKO pups) received 1x1011 particles of dsAAV8-CMV-GH at the 10th and 11th days of life (high dose); GFP group (6 GHRHKO pups) received 1x1011 particles of dsAAV8-CMV-GFP; and placebo groups (Plac) (12 GHRHKO pups per group) received placebo injections. Control groups (Ctl) consisted of 12 pups heterozygous (HTZ) for GHRHKO gene. HD, GFP, and one half (six mice) of LD, Plac, and Ctl groups were killed at the 6th week of age. The other half of LD, Plac, and Ctl groups were allowed to reach the 24th week of age (long-term groups).
|
Auxological data
Starting from the first week of life, all pups were examined weekly for 5 weeks (LD, HD, GFP, Plac, and Ctl groups) or for 23 weeks (LD, Plac, and Ctl long-term groups) by measuring total body weight (TBW) using a daily-calibrated electronic balance (Scout Pro Balance; Ohaus Corp SP601, Pine Brook, NJ, USA) and body length (nose-to-anus distance, N-A), using an electronic digital caliper (Fisher brand Traceable Digital Caliper; Fisher Scientific, Hampton, NH, USA). Two days before the end of the study, animals were anesthetized using Avertin (tribromoethanol; Sigma–Aldrich) and 
200 µl blood were collected with heparinized capillaries by retro-orbital bleed for GH and IGF-I measurements. Following the same method at the 10th, 14th, 18th, 22nd weeks of life, we collected blood from four mice of LD and Ctl long-term groups for IGF-I measurements. Serum was stored at –20 °C until the day of assay. Mice were killed by halothane overdose. After killing, we harvested heart, liver, spleen, right kidney, right testis, and right gastrocnemius muscle. Organs were weighed using an Ohaus Adventurer Pro Analytical Balance (AV264 Ohaus, Pine Brook, NJ, USA). Femur and tibia length were measured using an electronic caliper after dissection of the surrounding tissues and careful disarticulation of the bones. Right femur length was considered as the maximal distance between the head of the great trochanter and the distal condyles, while right tibia length as the maximal distance between proximal condyles and malleolus. To determine the effects of the GH expression on body composition, animals were skinned, the perirenal and epidydimal fat pads were pooled (visceral fat, VF), while the sum of fat pads from the interscapular and axillary region, thighs, and inguinal region was considered s.c. fat (SF). Lean mass (LM) was measured by weighing animals deprived of tail, skin, adipose tissue, and internal organs. LM, VF, and SF weights of each animal were normalized to TBW by calculating the percentage as follows: (weight (g)/TBW (g))x100.
Detection of GH RNA expression
Total RNA was isolated using TRIzol reagent (Invitrogen, Life Technologies) according to the manufacturer's recommendations. We used 25/50 mg of tissue/mice from liver, heart, right gastrocnemius muscle, spleen, right kidney, and right testis. Total RNA was quantified spectrophotometrically at 260 nm (DU 640 Spectrophotometer; Beckman-Coulter, Fullerton, CA, USA). One microgram of total RNA was used to generate cDNA using reverse transcriptase (Moloney murine leukemia virus (M-MLV) Reverse Transcriptase; Promega). Control tubes were used without reverse transcriptase (reverse transcriptase negative). GH cDNA was amplified by PCR using primers described above, expected to generate an 859 bp band corresponding to the full-length mouse GH cDNA.
Serum hormones measurements
We measured serum GH and IGF-I at the 6th week of age in LD, HD, GFP, Plac, and Ctl groups. In addition, IGF-I serum levels were measured at the 10th, 14th, 18th, and 22nd weeks of age in four mice from LD and Ctl, and at the 24th week of age in long-term LD, Plac, and Ctl groups. GH serum levels were measured at the 24th week in four mice from LD, Plac, and Ctl groups.
Serum GH was measured by RIA (Rat GH RIA, RGH-45HK; Linco-Millipore, Billerica, MA, USA). The standard curve of the assay performed in accordance with the manufacturer's provided samples. Each sample was assayed in duplicate.
Serum IGF-I was measured using mouse/rat IGF-I kit (DSL-2900; DSL Webster, TX, USA), after acid–ethanol extraction, following the manufacturer's recommendations. The assay included quality controls provided by the manufacturer. The standard curve of the assay performed in accordance with the manufacturer's provided samples. Each sample was assayed in duplicate.
Fluorescence analysis
Tissues were fixed in 4% paraformaldyde (PFA, pH 7.3), washed in 0.2 M PO4 buffer, and conserved –20 °C in Tissue-Teck OCT Compound. Transversal sections (7 µm) were cut from frozen tissue. All tissues were placed on glass slides and covered by 25 µl Vectashield Mounting Medium (Vector Laboratories Inc., Burlingame, CA, USA) containing propidium iodine for direct evaluation of GFP expression under the fluorescence microscope.
Statistical analysis
Data were analyzed by ANOVA using the SPSS statistical package (SPSS Inc., Chicago, IL, USA), with post hoc analysis using Bonferroni's method. Data were considered statistically significant at P<0.05.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
As shown in Fig. 1A and B, all groups of GHRHKO mice injected with dsAAV8-CMV-GH virus reached significant increase in the final N-A length (6 and 24 weeks). At the 6th week of age N-A length of HD group was significantly higher than LD and Ctl groups. Weight normalized in all virus-treated groups at the 6th and 24th weeks of age (Fig. 2A and B). As shown in Fig. 3A–C, both low- and high-dose-treated groups at the 6th and 24th weeks of age normalized in femoral and tibial lengths.
|
|
|
|
|
GH mRNA was detected by RT-PCR only in liver, skeletal, and heart muscle of virus-injected animals both at the 6th (Fig. 5A) and 24th weeks (Fig. 5B), but not in spleen, kidney, and testis.
|
As shown in Fig. 6A, at 6 weeks of age GH levels of low- and high-dose groups were significantly higher than levels of HTZ control mice. Serum GH levels of control mice were higher than placebo- and GFP-treated animals. At 24 weeks of age, serum GH levels of virus-treated mice were higher than placebo but not different from HTZ mice (Ctl; Fig. 6B).
|
As shown in Fig. 7A, at 6 weeks of age, serum IGF-I levels were significantly higher in the high-dose-treated group compared with heterozygous mice, but no statistically significant difference was observed between low dose and HTZ controls. Serum IGF-I levels were significantly higher in both groups treated with dsAAV8-GH virus than in placebo-treated GHRHKO mice and mice treated dsAAV8-CMV-GFP. There was no statistical difference between serum IGF-I levels in the low-dose-treated group and HTZ mice at the 10th, 14th, 18th, 22nd, and 24th weeks of age, and they were both higher than in placebo-treated GHRHKO mice at week 24 (Fig. 7B).
|
Microscopy analysis showed that in GHRHKO mice injected with dsAAV8-CMV-GFP, GFP was expressed in liver, skeletal, and (to a lesser extent) heart muscle, while no detectable expression was observed in spleen and kidney in agreement with the result of GH mRNA in mice injected with dsAAV8-CMV-GH (Fig. 8A). No fluorescence was observed in tissues from HTZ mice (Fig. 8B).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The detection of normal levels of serum GH and IGF-I at 24 weeks of life (22.5 weeks after the injection of the virus) confirmed previous studies showing that this viral vector has stable and long-term expression limited to the liver, skeletal, and cardiac muscle (McClane et al. 1997, Song et al. 2001, Tsai et al. 2002, Ayuso et al. 2004, Arruda et al. 2005, Lai et al. 2005, Rehman et al. 2005, Zhu et al. 2005, Wang et al. 2006). This is confirmed by both detection of GH mRNA and fluorescence studies in mice injected with GFP-expressing vector. The pattern of expression (as shown by GH mRNA) was similar at 6 and 24 weeks, suggesting stable and long-term gene expression after the initial infection. Our results are similar to previous works that has used single-stranded adenoviral vector that caused expression of recombinant GH up to 7 weeks (Hahn et al. 1996). In that paper, however, expression beyond 7 weeks was not assessed, and tissue expression of the virus was not examined. Another GH delivery system using a single-stranded adeno-associated virus has been shown to last up to 10 months after a single injection, but it is used in nude mice unable to mount an immune response (Rivera et al. 1999). Therefore, our results show that in GHD immunocompetent mice a species-specific GH cDNA continue to exert biological activity up to 6 months from a single injection.
Serum levels of GH at 6 weeks in the low-dose group were higher than at 24 weeks, showing that the degree of GH expression reduces over time. This reduction did not reflect a parallel decrease in serum IGF-I. This is not completely surprising. Serum IGF-I reflects mostly liver IGF-I production, and in the past we have noted a frequent discrepancy between the effects of GH or GHRH on growth and serum IGF-I, which seems to be a less than optimal index of GH effect in mice (Alba et al. 2005a, Fintini et al. 2005a,b). Indeed, in mice with liver-specific ablation of the IGF-I gene, somatic growth is essentially normal despite markedly reduced serum IGF-I (Yakar et al. 1999). Nevertheless, the fact that serum IGF-I levels at 24 weeks are significantly higher in virus-treated than in placebo-treated GHRHKO mice shows that the expressed GH is still functional, and that no resistance to its effect developed over time. This is not surprising, as we have used a species-specific GH cDNA, and previous reports describing the development of anti-GH antibodies in GH-treated GHD rodents used exogenous GH from different species (Groesbeck & Parlow 1987). As we do not have a group that was allowed to survive longer than 6 months, we cannot determine whether eventually the transgene expression would disappear. However, long-term gene expression over a year mediated by AAV vectors in experimental animals has been well documented in different animal species using various transgenes (Rivera et al. 2005). The positive effect of the dsAAV virus on growth was not accompanied by any readily evident side effect, despite the fact that GH expression was not physiologically regulated. Obviously, the use of a universal promoter is a limitation to any possible clinical application of this approach, due to the well-known long-term risks associated with excessive and unregulated GH secretion as seen in patients with GH-secreting pituitary adenomas (Melmed 2006). In addition, cardiac expression and possible long-term effects of locally produced GH on the heart muscle is also a concern (Lombardi et al. 1997). Therefore, future studies are being designed using either inducible promoters (that may be regulated at will), similarly to the data published by Rivera et al. (1999), or promoters that are specific for a given tissue (e.g. muscle) which may allow significant systemic delivery despite limited local expression. Finally, the occurrence of circulating anti-AAV antibodies has been reported in rodents (Peden et al. 2004) and liver enzyme increase has been reported in human hemophilic subjects treated with intrahepatic AAV vector expressing factor IX (Manno et al. 2006). All these factors may limit future clinical use of this approach.
While the applicability of the findings of this work is very far from any conceivable clinical application in humans, the advantages of new dsAAV vectors offer a good starting point for the development of novel regulated viral gene delivery systems for GH administration.
|
Acknowledgements |
|---|
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Afione SA, Wang J, Walsh S, Guggino WB & Flotte TR 1999 Delayed expression of adeno associated virus vector DNA. Intervirology 42 213–220.[CrossRef][Web of Science][Medline]
Alba M & Salvatori R 2004 A mouse with targeted ablation of the growth hormone-releasing hormone gene: a new model of isolated growth hormone deficiency. Endocrinology 145 4134–4143.
Alba M, Fintini D & Salvatori R 2005a Effects of recombinant mouse growth hormone treatment on growth and body composition in GHRH knock out mice. Growth Hormone and IGF Research 15 275–282.[CrossRef]
Alba R, Bosch A & Chillon M 2005b Gutless adenovirus: last-generation adenovirus for gene therapy. Gene Therapy 1 S18–S27.
Arruda VR, Stedman HH, Nichols TC, Haskins ME, Nicholson M, Herzog RW, Couto LB & High KA 2005 Regional intravascular delivery of AAV-2-FIX to scheletal muscle achieves long-term correction of hemophilia B in large animal model. Blood 105 3458–3464.
Ayuso E, Chillon M, Agudo J, Haurigot V, Bosch A, Carretero A, Otaegui PJ & Bosch F 2004 In vivo gene transfer to pancreatic beta cells by systemic delivery of adenoviral vectors. Human Gene Therapy 15 805–812.[CrossRef][Web of Science][Medline]
Bangari DS & Mittal SK 2006 Current strategies and future directions for eluding adenoviral vector immunity. Current Gene Therapy 6 215–226.[CrossRef][Web of Science][Medline]
Beamer WG & Eicher EM 1976 Stimulation of growth in little mouse. Journal of Endocrinology 71 37–45.
Berns KI & Giraurd C 1995 Adenovirus and adeno-associated virus as vectors for gene therapy. Annals of the New York Academy of Sciences 772 95–104.[CrossRef][Web of Science][Medline]
Berns KI & Hauswirth WW 1979 Adeno-associated viruses. Advances in Virus Research 25 407–449.[Medline]
Bryant J, Cave C, Mihaylova B, Chase D, McIntyre L, Gerard K & Milne R 2002 Clinical effectiveness and cost effectiveness of growth hormone in children: a systemic review and economic evaluation. Health Technology Assessment 6 100–106.
Coschigano KT, Holland AN, Riders ME, List EO, Flyvberg A & Kopchick JJ 2003 Delection, but non antagonism, of the mouse growth hormone receptor result in severely decreased body weights, insulin, and insulin like growth factor I levels and increased life span. Endocrinology 144 3799–3810.
Ferrari FK, Samulski T, Shenk T & Samulski RJ 1996 Second-strand synthesis in a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. Journal of Virology 70 3227–3234.[Abstract]
Fintini D, Alba M & Salvatori R 2005a Influence of estrogen administration on the growth response to growth hormone (GH) in GH-deficient mice. Experimental Biology Medicine 230 715–720.
Fintini D, Alba M, Schally AV, Bowers CY, Parlow AF & Salvatori R 2005b Effects of combined long-term treatment with a GHRH analog and GHRP-2 in the GHRH knock out mouse. Neuroendocrinology 82 198–207.[CrossRef][Web of Science][Medline]
Flint DJ, Binart N, Kopchick JJ & Kelly P 2003 Effects of growth hormone and prolactin of adipose tissue development and function. Pituitary 6 97–102.[CrossRef][Medline]
Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J & Wilson JM 2002 Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. PNAS 99 11854–11859.
Giustina A & Veldhuis JD 1998 Pathophysiology of the neuroregulation of growth hormone secretion experimental animals and human. Endocrine Reviews 19 717–797.
Groesbeck MD & Parlow AF 1987 Highly improved precision of the hypophysectomised female rat body weight gain bioassay for growth hormone by increased frequency of injections, avoidance of antibody formation, and other simple modifications. Endocrinology 120 2582–2590.
Groesbeck MD, Parlow AF & Daughaday WH 1987 Stimulation of supranormal growth in prepubertal, adult plateued and hypophysectomized female rats by large doses of rat growth hormone: physiological effects and adverse consequence. Endocrinology 120 1963–1975.
Hahn TM, Copeland KC & Woo SL 1996 Phenotypic correction of dwarfism by constitutive expression of growth hormone. Endocrinology 137 4988–4993.[Abstract]
Hanley MB, Napolitano LA & McCune JM 2005 Growth hormone-induced stimulation of multilineage human hemopoiesis. Stem Cells 23 1170–1179.
Hindmarsh PC & Dattani MD 2006 Use of growth hormone in children. Nature Clinical Practice. Endocrinology and Metabolism 2 260–268.[CrossRef]
Lai LJ, Lin KK, Foulks GN, Ma L, Xiao X & Chen KH 2005 Highly efficient ex vivo gene delivery into human corneal endothelial cells by recombinant adeno-associated virus. Current Eye Research 30 213–219.[CrossRef][Web of Science][Medline]
Lombardi G, Colao A, Ferone D, Marzullo P, Orio F, Longobardi S & Merola B 1997 Effect of growth hormone on cardiac function. Hormone Research 4 38–42.
Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, Ozelo MC, Hoots K, Blatt P, Konkle B et al. 2006 Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nature Medicine 12 342–347.[CrossRef][Web of Science][Medline]
Marmary Y, Parlow AF, Goldsmith CM, He X, Wellner RB, Satomura K, Kriete MF, Robey PG, Nieman LK & Baum BJ 1999 Construction and in vivo efficacy of a replication-deficient recombinant adenovirus encoding murine growth hormone. Endocrinology 140 260–265.
McClane SJ, Chirmule N, Burke CV & Raper SE 1997 Characterization of the immune response after local delivery of recombinant adenovirus in murine pancreas and successful strategies for redministration. Human Gene Therapy 8 2207–2216.[Web of Science][Medline]
Melmed S 2006 Medical progress: Acromegaly. New England Journal of Medicine 355 2558–2573.
Peden CS, Burger C, Muzyczka N & Mandel RJ 2004 Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. Journal of Virology 52 192–201.
Rehman KK, Wang Z, Bottino R, Balamurugan AN, Trucco M, Li J, Xiao X & Robbins PD 2005 Efficient gene delivery to human and rodent islets with double-stranded (ds) AAV-based vectors. Gene Therapy 12 1313–1323.[CrossRef][Web of Science][Medline]
Rivera VM, Ye X, Courage NL, Sachar J, Cerasoli F, Wilson JM & Gilman M 1999 Long-term regulated expression of growth hormone in mice after intramuscular gene transfer. PNAS 96 8657–8662.
Rivera VM, Gao GP, Grant RL, Schnell MA, Zoltick PW, Rozamus LW, Clackson T & Wilson JM 2005 Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood 105 1424–1430.
Le Roith D, Bondy C, Yakar S, Liu JL & Butler A 2001 The somatomedin hypothesis. Endocrine Reviews 22 53–74.
Saggese G, Ranke MB, Saenger P, Rosenfeld RG, Tanaka T, Chaussain JL & Savage MO 1998 Diagnosis and treatment of growth hormone deficiency in children and adolescents: towards a consensus. Ten years after the availability of recombinant human growth hormone workshop held in Pisa, Italy, 27–28 March 1998. Hormone Research 50 320–340.[CrossRef][Medline]
Salvatori R 2004 Growth hormone and IGF-1. Reviews in Endocrine and Metabolic Disorders 5 15–23.[CrossRef]
Samulski RJ, Sally M & Muzjckza N 1999 Adeno-associated viral vector. Development of human gene therapy, pp 131–172. Ed T Friedmann. Cold Spring Harbor: Cold Spring Harbor Laboratory Press.
Snyder R, Xiao X & Samulski RJ 1996 Production of recombinant adeno-associated viral vectors. In Current Protocols in Human Genetics , pp 12.1.1–12.2.23. Eds D Smith. New York: Wiley.
Song S, Embury J, Laipis J, Berns KI, Crawford JM & Flotte TR 2001 Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors. Gene Therapy 8 1299–1306.[CrossRef][Web of Science][Medline]
Tsai TH, Chen SL, Xiao X, Liu DW & Tsao YP 2002 Gene therapy for treatment of cerebral ischemia using defective recombinant adeno-associated virus vectors. Methods 28 253–258.[CrossRef][Web of Science][Medline]
Vickers MH, Ikenasio BA & Breier BH 2002 Adult growth hormone treatment reduces hypertension and obesity induced by an adverse prenatal environment. Journal of Endocrinology 175 615–623.[Abstract]
Wang Z, Ma HI, Li J, Sun L, Zhang J & Xiao X 2003 Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Therapy 10 2105–2111.[CrossRef][Web of Science][Medline]
Wang Z, Zhu T, Qiao C, Zhou L, Wang B, Zhang J, Chen C, Li J & Xiao X 2005 Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nature Biotechnology 23 321–328.[CrossRef][Web of Science][Medline]
Wang Z, Zhu T, Rehman KK, Bertera S, Zhang J, Chen C, Papworth G, Watkins S, Trucco M, Robbins PD et al. 2006 Widespread and stable pancreatic gene transfer by adeno-associated virus vectors via different routes. Diabetes 55 875–884.
Woodall SM, Breir BH, O'Sulliavan UO & Gluckman PD 1991 The effect of the frequency of subcutaneous insulin-like growth factor-1 administration on weight gain in growth hormone deficient mice. Hormone Metabolic Research 23 581–584.
Xiao X, Li J & Samulski RJ 1998 Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. Journal of Virology 72 2224–2232.
Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B & LeRoith D 1999 Normal growth and development in the absence of hepatic insulin-like growth factor I. PNAS 96 7324–7329.
Zhu T, Zhou L, Mori S, Wang Z, McTiernan CF, Qiao C, Chen C, Wang DW, Li J & Xiao X 2005 Sustained whole-body functional rescue in congestive heart failure and muscular dystrophy hamsters by systemic gene transfer. Circulation 112 2650–2659.
Received in final form 12 September 2007
Accepted 17 October 2007
Made available online as an Accepted Preprint 17 October 2007
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
